Christina Petersson

As CIPO and Head of IPR & Licensing at Ericsson since 2019, Christina Petersson is responsible for Ericsson’s patent development and patent licensing worldwide. Ericsson is one of the leading providers of Information and Communication Technology (ICT) to service providers, investing heavily in R&D as a leading contributor to open standards. With more than 54,000 granted patents, Ericsson has the industry’s leading patent portfolio, covering 2G, 3G, 4G and now 5G cellular standards. Ms Petersson’s previous role was Vice President and Head of IPR Legal Affairs at Ericsson. In this role, which she held since 2011, Ms Petersson had an active role in licensing negotiations and has been responsible for concluding license agreements with the vast majority of Ericsson’s more than 100 licensees.  Ms Petersson has worked at Ericsson since 1998 when she started her career as a Trademark Attorney.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More